gold-safetyandefficacy-2014.pdf (1.87 MB)
Safety and efficacy of antenatal milk expressing for women with diabetes in pregnancy: protocol for a randomised controlled trial
journal contribution
posted on 2014-10-30, 00:00 authored by D A Forster, S Jacobs, L H Amir, P Davis, S P Walker, K McEgan, G Opie, S M Donath, A M Moorhead, R Ford, C McNamara, A Aylward, Lisa GoldLisa GoldMany maternity providers recommend that women with diabetes in pregnancy express and store breast milk in late pregnancy so breast milk is available after birth, given (1) infants of these women are at increased risk of hypoglycaemia in the first 24 h of life; and (2) the delay in lactogenesis II compared with women without diabetes that increases their infant's risk of receiving infant formula. The Diabetes and Antenatal Milk Expressing (DAME) trial will establish whether advising women with diabetes in pregnancy (pre-existing or gestational) to express breast milk from 36 weeks gestation increases the proportion of infants who require admission to special or neonatal intensive care units (SCN/NICU) compared with infants of women receiving standard care. Secondary outcomes include birth gestation, breastfeeding outcomes and economic impact.
History
Journal
BMJ openVolume
4Issue
10Article number
e006571Pagination
1 - 9Publisher
BMJ GroupLocation
London, EnglandPublisher DOI
eISSN
2044-6055Language
engPublication classification
C Journal article; C1 Refereed article in a scholarly journalCopyright notice
2014, BMJ GroupUsage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC